查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970738

真性紅血球增多症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭對手分類，2021-2031年

Polycythemia Vera Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球真性紅血球增多症治療市場預計將從 2025 年的 31.4 億美元成長到 2031 年的 48.7 億美元，複合年成長率為 7.59%。

該市場涵蓋用於治療紅血球增多症和降低血栓風險的細胞收縮劑、干擾素製劑和JAK抑制劑。推動市場成長的根本因素是易患骨髓增生性腫瘤的老年人口不斷增加，以及分子診斷技術的進步使得疾病早期檢測成為可能。這些關鍵促進因素預計將持續滿足對慢性病管理解決方案的需求，從而帶來與行業短期波動截然不同的穩定成長。

市場概覽
預測期 2027-2031
市場規模：2025年 31.4億美元
市場規模：2031年 48.7億美元
複合年成長率：2026-2031年 7.59%
成長最快的細分市場 Dasatinib
最大的市場 北美洲

然而，慢性藥物治療的安全性問題在該領域引發了許多挑戰，這往往阻礙了新治療方法的推廣應用。近期的使用數據顯示，傳統治療方法仍佔據主導地位，這種對新治療方法的抗拒情緒顯而易見。根據美國血液學會（ASH）2024年的數據，49.2%的真性紅血球增多症患者正在接受羥基脲治療，而使用新型藥物洛培干擾素的患者僅佔1.2%。這些數據凸顯了創新藥物在試圖取代現有治療方法時所面臨的主要障礙。

市場促進因素

對於羥基脲抗藥性患者以及嚴重依賴治療性放血療法的患者而言，未被滿足的需求是推動該領域創新發展的主要動力。目前的標準治療方法往往難以維持血球比容，且需要頻繁進行侵入性操作，導致患者生活品質下降，血栓風險降低不足。這個臨床缺口正推動著替代機制的研究和開發，例如鐵調素模擬藥物，旨在精準調控紅血球生成，同時避免細胞減滅療法的弊端。正如Protagonist Therapeutics在2024年5月的公司報告中所指出的，僅在美國就有約10萬名真性紅血球增多症患者目前接受放血療法治療，這代表著非細胞減滅療法的巨大潛在市場。

新型JAK抑制劑和新一代干擾素的快速核准和商業化，憑藉其卓越的疾病管理療效，進一步推動了市場擴張。製藥公司正積極推廣這些標靶治療，利用其高臨床應用率帶來的收入基礎，並有望取代傳統的學名藥。這種向高價值生物製藥的轉變，從主要市場參與者的財務表現中可見一斑。例如，Incyte公司在2024年2月報告稱，其JAK抑制劑Jakaffi的年度淨產品銷售額達到26億美元，證明了標靶抑制療法的經濟可行性。此外，長期療效數據不斷增強處方醫生的信心；PharmaEssentia公司在2024年公佈的臨床結果顯示，接受lopegintaferone alfa-2b治療的患者無血栓症生存率高達96%，這證明了轉向緩解疾病療法的合理性。

市場挑戰

長期藥物治療的安全性問題是全球真性紅血球增多症治療市場成長的一大障礙。儘管分子診斷技術的進步使得疾病的早期檢測成為可能，但新療法頻繁出現不利事件的報告阻礙了其應用。這種「安全至上」的策略使得市場仍然專注於低成本的傳統療法，即使高價新藥的推出可能帶來收入成長，也阻礙了市場的發展。只要患者和臨床醫生認為，與現有的標準療法相比，先進藥物在生活品質方面的權衡取捨並不理想，這些創新藥物的市場滲透率就將持續受限。

近期關於病患耐受性的對比安全性數據凸顯了這項挑戰。根據美國血液學會2024年發表的一項真實世界臨床數據分析，80%接受干擾素治療的患者在治療期間出現疼痛，這一發生率顯著高於使用羥基脲的患者（47.4%）。這些數據表明，人們普遍對放棄傳統標準療法持猶豫態度，並直接阻礙了新興藥物類別在市場上的商業性擴張。

市場趨勢

用於控制血球容積比的鐵調素類似藥物的出現，正透過非細胞增生機​​制改變著紅血球增多症的治療模式。與廣泛抑制骨髓功能的傳統療法不同，這些藥物嚴格調控鐵穩態以限制紅血球生成，直接克服了治療性放血的限制。後期臨床試驗的進展也支持了這一趨勢，這些試驗表明，對於接受標準治療的患者，這些藥物有望消除侵入性維持治療。例如，Protagonist Therapeutics公司於2025年6月報告稱，在其III期VERIFY試驗中，鐵調素類似藥物rusfeltide組76.9%的患者達到了「無需放血」的主要終點，而安慰劑組僅為32.9%。這顯示藥物介導的鐵限制療法正成為一種重要的治療手段。

洛培干擾素α-2b作為一線治療藥物的加速普及，清楚地表明市場正從仿單標示外干擾素的使用轉向已通過核准的長效製劑。由於其能夠誘導深度分子反應並最大限度地減少給藥頻率，臨床醫生越來越傾向於優先選擇這種緩解疾病劑而非傳統治療方法。這種廣泛的商業性應用也體現在製藥公司財務的快速擴張上，因為它們從標準療法中獲得了非專利抗癌藥物的市場佔有率。根據PharmaEssentia截至2024年12月的會計年度財報，該公司年初至今的連合收益為86億新台幣，較去年同期成長94.15%。這主要得益於其旗艦產品真性紅血球增多症的全球銷售量成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：真性紅血球增多症治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（Dasatinib、伊德拉利西布、吉比司他、M-009、其他）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：真性紅血球增多症治療藥物北美市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲真性紅血球增多症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區真性紅血球增多症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲真性紅血球增多症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：真性紅血球增多症治療藥物在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球真性紅血球增多症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • ANP Technologies Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • Karus Therapeutics Limited
  • miRagen Therapeutics Inc.
  • Nerviano Medical Sciences Srl
  • Novartis AG
  • PharmaEssentia Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23945

The Global Polycythemia Vera Drug Market is projected to expand from USD 3.14 Billion in 2025 to USD 4.87 Billion by 2031, reflecting a compound annual growth rate of 7.59%. This market encompasses cytoreductive agents, interferon formulations, and JAK inhibitors utilized to manage erythrocytosis and reduce thrombotic risks. Growth is fundamentally driven by an increasing geriatric population prone to myeloproliferative neoplasms and advancements in molecular diagnostics that facilitate earlier disease detection. These core drivers ensure a continued demand for chronic management solutions, distinguishing this growth from temporary industry fluctuations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.14 Billion
Market Size 2031USD 4.87 Billion
CAGR 2026-20317.59%
Fastest Growing SegmentDasatinib
Largest MarketNorth America

However, the sector encounters notable hurdles regarding the safety profiles of chronic pharmacotherapy, which frequently hinder the uptake of novel treatments. This resistance to adopting new therapeutics is evident in recent utilization metrics where traditional options maintain dominance. Data from the American Society of Hematology in 2024 indicated that 49.2 percent of Polycythemia Vera patients were treated with hydroxyurea, whereas only 1.2 percent utilized the newer agent ropeginterferon. These figures emphasize the substantial barriers innovative drugs face when attempting to displace established regimens.

Market Driver

Unmet medical needs among patients resistant to hydroxyurea and those heavily reliant on therapeutic phlebotomy act as a primary catalyst for innovation within the sector. Current standard-of-care regimens often fail to sustain consistent hematocrit control, requiring frequent invasive procedures that lower patient quality of life and inadequately mitigate thrombotic risks. This clinical gap propels the research and development of alternative mechanisms, such as hepcidin mimetics, which aim to strictly regulate erythropoiesis without the drawbacks of cytoreductive therapies. As noted in a May 2024 corporate presentation by Protagonist Therapeutics, approximately 100,000 Polycythemia Vera patients in the United States alone are currently managed with phlebotomy, representing a massive addressable demographic for non-cytoreductive alternatives.

The accelerated approval and commercialization of novel JAK inhibitors and next-generation interferons further strengthen market expansion by providing superior disease control. Pharmaceutical companies are aggressively marketing these targeted therapies to supersede generic legacy drugs, supported by revenue streams that indicate high clinical uptake. This transition toward high-value biologics is evident in the financial performance of major market players; for example, Incyte reported in February 2024 that full-year net product revenues for the JAK inhibitor Jakafi reached $2.6 billion, demonstrating the financial viability of targeted inhibition. Additionally, long-term efficacy data continues to boost prescriber confidence, as PharmaEssentia presented clinical findings in 2024 showing that patients on ropeginterferon alfa-2b maintained a 96 percent thrombosis-free survival probability, validating the shift toward disease-modifying agents.

Market Challenge

The safety profiles associated with chronic pharmacotherapy constitute a significant impediment to the growth of the Global Polycythemia Vera Drug Market. Despite improvements in molecular diagnostics that allow for earlier disease detection, the adverse events linked to newer therapeutic classes frequently discourage their adoption. This safety-driven resistance anchors the market in low-cost, traditional regimens, stalling the revenue shifts expected from the uptake of premium, novel agents. When patients and clinicians view the quality-of-life trade-offs of advanced drugs as unfavorable compared to established standards, market penetration for these innovations remains limited.

This challenge is highlighted by recent comparative safety data regarding patient tolerability. Real-world analysis presented by the American Society of Hematology in 2024 indicated that 80 percent of patients treated with interferon formulations experienced pain during therapy, a notably higher incidence than the 47.4 percent observed in those utilizing hydroxyurea. Such statistics confirm the widespread hesitancy to switch from legacy standards, directly hampering the commercial expansion of the market's emerging drug classes.

Market Trends

The emergence of hepcidin mimetics for hematocrit control is transforming the therapeutic landscape by offering a non-cytoreductive mechanism to manage erythrocytosis. Unlike traditional therapies that suppress broad bone marrow activity, these agents strictly regulate iron homeostasis to limit red blood cell production, directly addressing the limitations of therapeutic phlebotomy. This trend is supported by late-stage clinical advancements validating their potential to eliminate invasive maintenance procedures for patients struggling with standard regimens. For instance, Protagonist Therapeutics reported in June 2025 that in the Phase 3 VERIFY study, 76.9 percent of patients treated with the hepcidin mimetic rusfertide achieved the primary endpoint of absence of phlebotomy eligibility compared to only 32.9 percent in the placebo group, signaling a major shift toward pharmaceutical iron restriction.

The accelerated adoption of Ropeginterferon alfa-2b as a first-line therapy represents a definitive market transition from off-label interferon use to approved, long-acting formulations. Clinicians are increasingly prioritizing this disease-modifying agent over legacy treatments due to its ability to induce deep molecular responses and minimize administration frequency. This widespread commercial uptake is reflected in the rapid financial expansion of the drug's manufacturer as it gains market share from generic cytoreductive standards. As per PharmaEssentia's December 2024 revenue report, the company achieved a year-to-date consolidated revenue of NT$8.60 billion, representing a 94.15 percent increase compared to the prior year, driven principally by the global volume expansion of its flagship polycythemia vera therapy.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • ANP Technologies Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences
  • Karus Therapeutics Limited
  • miRagen Therapeutics Inc.
  • Nerviano Medical Sciences S.r.l.
  • Novartis AG
  • PharmaEssentia Corporation

Report Scope

In this report, the Global Polycythemia Vera Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polycythemia Vera Drug Market, By Type

  • Dasatinib
  • Idelalisib
  • Givinostat
  • M-009
  • Others

Polycythemia Vera Drug Market, By End User

  • Hospitals& Clinics
  • Ambulatory Care Centers
  • Others

Polycythemia Vera Drug Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycythemia Vera Drug Market.

Available Customizations:

Global Polycythemia Vera Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Polycythemia Vera Drug Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Dasatinib, Idelalisib, Givinostat, M-009, Others)
    • 5.2.2. By End User (Hospitals& Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Polycythemia Vera Drug Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Polycythemia Vera Drug Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Polycythemia Vera Drug Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Polycythemia Vera Drug Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Polycythemia Vera Drug Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Polycythemia Vera Drug Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Polycythemia Vera Drug Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Polycythemia Vera Drug Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Polycythemia Vera Drug Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Polycythemia Vera Drug Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Polycythemia Vera Drug Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Polycythemia Vera Drug Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Polycythemia Vera Drug Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Polycythemia Vera Drug Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Polycythemia Vera Drug Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Polycythemia Vera Drug Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Polycythemia Vera Drug Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Polycythemia Vera Drug Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Polycythemia Vera Drug Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Polycythemia Vera Drug Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. South America Polycythemia Vera Drug Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Polycythemia Vera Drug Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Polycythemia Vera Drug Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Polycythemia Vera Drug Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Polycythemia Vera Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ANP Technologies Inc.
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Gilead Sciences
  • 15.6. Karus Therapeutics Limited
  • 15.7. miRagen Therapeutics Inc.
  • 15.8. Nerviano Medical Sciences S.r.l.
  • 15.9. Novartis AG
  • 15.10. PharmaEssentia Corporation

16. Strategic Recommendations

17. About Us & Disclaimer